Please assess the completion status of the following clinical trial:

Trial Title: Effect of Empagliflozin on Macrovascular and Microvascular Circulation and on Endothelium Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus defined by fasting glucose ≥ 126 mg/dl or HbA1c ≥ 6.5% or on blood glucose lowering medication~* Age of 18 - 75 years~* Male and Female patients (females of child bearing potential must be using adequate contraceptive precautions)~* Females of childbearing potential or within two years of the menopause must have a negative urine pregnancy test at screening visit~* Informed consent (§ 40 Abs. 1 Satz 3 Punkt 3 AMG) has to be given in written form.~Exclusion Criteria:~* Any other form of diabetes mellitus than type 2 diabetes mellitus~* Use of insulin, glitazone, gliptine or SGLT-2 inhibitor within the past 3 months~* Patients with more than one oral blood glucose lowering medication~* Any other oral antidiabetic drug that cannot be discontinued for the study period~* HbA1c ≥ 10%~* Fasting plasma glucose \> 240 mg/dl~* Any history of stroke, transient ischemic attack, instable angina pectoris, or myocardial infarction within the last 6 months prior to study inclusion~* UACR ≥ 300 mg/g (early morning spot urine)~* eGFR \< 60 ml/min/1.73m²~* Uncontrolled arterial hypertension (RR ≥ 180/110 mmHg)~* Congestive heart failure (CHF) NYHA stage III and IV~* Severe disorders of the gastrointestinal tract or other diseases which interfere the pharmacodynamics and pharmakinetics of study drugs~* Significant laboratory abnormalities such as SGOT or SGPT levels more than 3 x above the upper limit of normal range~* Drug or alcohol abusus~* Pregnant or breast-feeding patients~* Use of loop diuretics~* History of repetitive urogenital infection per year~* Body mass index \> 40 kg/m²~* Triglyceride levels \> 1000 mg/dl~* HDL-cholesterol levels \< 25 mg/dl~* Any patient currently receiving chronic (\>30 consecutive days) treatment with an oral corticosteroid~* History of epilepsia or history of seizures~* Patients being treated for severe auto immune disease e.g. lupus~* Participation in another clinical study within 30 days prior to visit 1~* Individuals at risk for poor protocol or medication compliance~* Subject who do not give written consent, that pseudonymous data will be transferred in line with the duty of documentation and the duty of notification according to § 12 and § 13 GCP-V

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Empagliflozin (Type: ACTIVE_COMPARATOR): Empagliflozin, 25 mg/day, oral administration, 6 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo, oral administration, 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).